Home > Insider Trading > Filing (0000947871-19-000983)

Filing Details

Accession Number:: 0000947871-19-000983
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-12-20 13:58:48
Reporting Period:: 2019-12-18

Accepted Time:: 2019-12-20 13:58:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1739174	Biomx Inc.	PHGE	()	L3

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1569590	Ltd. Gp Israel Orbimed	89 Medinat Hayehudim St., Building E Herzliya L3 4614001		Yes	No	Yes	No
1569821	Partnership Limited Gp Biofund Israel Orbimed	89 Medinat Hayehudim St., Building E Herzliya L3 4614001		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value	Acquisiton	2019-12-18	500	$8.93	2,309,989	No	4	P	Indirect	See Footnotes
Common Stock, $0.001 Par Value	Acquisiton	2019-12-19	3,500	$8.90	2,313,489	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

The purchases reported on this Form 4 were made by OrbiMed Israel Partners Limited Partnership ("OIP LP"). Following the transactions reported on this Form 4, OIP LP is the direct owner of 1,672,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII LP") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of each of OIP LP and OII LP.
By virtue of the relationships described in footnote 1, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP LP and OII LP and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Jonathan T. Silverstein, Nissim Darvish, Anat Naschitz and Erez Chimovits. Erez Chimovits, a member of the Issuer's board of directors, is an employee of OrbiMed Israel.
This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.